ArticleFASEB journal : official publication of the Federation of American Societies for Experimental Biology2026
RETRACTION: Connexin 43 Gap Junctions Contribute to Brain Endothelial Barrier Hyperpermeability in Familial Cerebral Cavernous Malformations Type III by Modulating Tight Junction Structure.
Article in FASEB journal : official publication of the Federation of American Societies for Experimental Biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
- Retraction of
Authors and funding
0 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
retractionA. M. Johnson, J. P. Roach, A. Hu, S. M. Stamatovic, M. R. Zochowski, R. F. Keep, A. V. Andjelkovic, "Connexin 43 Gap Junctions Contribute to Brain Endothelial Barrier Hyperpermeability in Familial Cerebral Cavernous Malformations Type III by Modulating Tight Junction Structure," The FASEB Journal 32, no. 5 (2018): 2615-2629, https://doi.org/10.1096/fj.201700699r. The above article, published online on 2 January 2018 in Wiley Online Library (wileyonlinelibrary.com), has been retracted by agreement between the journal Editor-in-Chief, Dr. Loren E. Wold; the Federation of American Societies for Experimental Biology; and Wiley Periodicals, LLC. The journal received concerns by a third-party regarding Figure 2A. Specifically, Figure 2A included apparent image reuse, relabeling, and misidentification of the identity of the protein probed in immunoblots, which has a subsequent impact on the reliability of quantification of protein lysates. Further investigation by the journal led to concerns of splicing in Supplemental Figure 1C. While the authors were able to provide the intact raw data for the supplemental immunoblot, the concerns regarding Figure 2A were not resolved. The retraction has been agreed to because of the evidence of image and data manipulation in Figure 2A fundamentally compromises the editors' confidence in the conclusions presented. The corresponding author, Anuska V. Andjelkovic, disagrees with the retraction and stated that the original data are available at a public data repository, the link to which is available by request to the authors. All other authors did not respond when informed of the retraction.
Identifiers
42836500What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.